RBF Capital LLC Purchases 369,620 Shares of Cardlytics, Inc. (NASDAQ:CDLX)

RBF Capital LLC grew its stake in shares of Cardlytics, Inc. (NASDAQ:CDLX - Free Report) by 311.9% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 488,128 shares of the company's stock after buying an additional 369,620 shares during the period. RBF Capital LLC owned 0.96% of Cardlytics worth $1,562,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of CDLX. Vanguard Group Inc. boosted its holdings in shares of Cardlytics by 2.7% during the first quarter. Vanguard Group Inc. now owns 2,211,595 shares of the company's stock worth $32,046,000 after purchasing an additional 57,805 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in shares of Cardlytics by 6.3% during the first quarter. Price T Rowe Associates Inc. MD now owns 29,769 shares of the company's stock worth $432,000 after purchasing an additional 1,774 shares during the last quarter. Canton Hathaway LLC boosted its holdings in shares of Cardlytics by 95.7% during the second quarter. Canton Hathaway LLC now owns 4,500 shares of the company's stock worth $37,000 after purchasing an additional 2,200 shares during the last quarter. Bank of New York Mellon Corp boosted its holdings in shares of Cardlytics by 15.4% during the second quarter. Bank of New York Mellon Corp now owns 135,924 shares of the company's stock worth $1,116,000 after purchasing an additional 18,179 shares during the last quarter. Finally, Ingalls & Snyder LLC boosted its holdings in Cardlytics by 106.0% in the second quarter. Ingalls & Snyder LLC now owns 32,464 shares of the company's stock valued at $267,000 after acquiring an additional 16,708 shares during the last quarter. Hedge funds and other institutional investors own 68.10% of the company's stock.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the company. Northland Securities cut Cardlytics from an "outperform" rating to a "market perform" rating and reduced their target price for the company from $7.00 to $5.00 in a report on Friday, August 16th. Craig Hallum upgraded Cardlytics from a "hold" rating to a "strong-buy" rating in a report on Wednesday, November 6th. Bank of America cut Cardlytics from a "neutral" rating to an "underperform" rating and reduced their price objective for the stock from $4.00 to $3.50 in a research note on Thursday, August 15th. Northland Capmk cut Cardlytics from a "strong-buy" rating to a "hold" rating in a research note on Friday, August 16th. Finally, Needham & Company LLC restated a "hold" rating on shares of Cardlytics in a research note on Thursday, November 7th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Hold" and an average price target of $6.92.

Insider Buying and Selling at Cardlytics

In other news, CFO Alexis Desieno sold 25,118 shares of the company's stock in a transaction on Friday, November 15th. The shares were sold at an average price of $3.43, for a total value of $86,154.74. Following the transaction, the chief financial officer now directly owns 116,481 shares of the company's stock, valued at approximately $399,529.83. This represents a 17.74 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Amit Gupta sold 22,607 shares of the company's stock in a transaction on Thursday, October 24th. The stock was sold at an average price of $3.85, for a total transaction of $87,036.95. Following the completion of the transaction, the chief executive officer now directly owns 178,519 shares in the company, valued at $687,298.15. This trade represents a 11.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 68,691 shares of company stock valued at $237,767 in the last three months. 4.40% of the stock is currently owned by company insiders.

Cardlytics Stock Performance

Shares of NASDAQ CDLX traded up $0.06 during midday trading on Thursday, hitting $3.88. 240,320 shares of the company's stock were exchanged, compared to its average volume of 1,201,565. The company has a debt-to-equity ratio of 2.40, a quick ratio of 1.18 and a current ratio of 1.18. The stock's 50 day moving average price is $3.81 and its 200-day moving average price is $5.67. Cardlytics, Inc. has a twelve month low of $2.89 and a twelve month high of $20.52.

Cardlytics (NASDAQ:CDLX - Get Free Report) last released its earnings results on Wednesday, November 6th. The company reported ($0.15) earnings per share for the quarter, topping analysts' consensus estimates of ($0.33) by $0.18. The firm had revenue of $67.06 million during the quarter, compared to the consensus estimate of $57.77 million. Cardlytics had a negative return on equity of 110.67% and a negative net margin of 93.55%. The firm's revenue for the quarter was down 15.1% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.26) earnings per share. As a group, equities analysts anticipate that Cardlytics, Inc. will post -1.52 earnings per share for the current fiscal year.

About Cardlytics

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.